NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has entered into a research collaboration with Ameritox to evaluate the use of Agilent's RapidFire platform in medication monitoring.

The RapidFire system is a high-throughput mass spectrometry platform that was developed for drug screening by Biocius, a spinout of BioTrove that Agilent acquired two years ago. The RapidFire 360 system was launched in May 2010 for the high-throughput screening of in vitro ADME assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.